Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
← catalyst calendarNCT05727904 · readout in 560 d
Sponsored by Iovance Biotherapeutics, Inc. (industry) · IOVA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
670estimated
Sites
81
Countries
Australia, Belgium, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-30 | actual | When the study began enrolling |
| Primary completion | 2028-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Melanoma
- Unresectable Melanoma
- Melanoma
Interventions
- Biological: Lifileucel plus Pembrolizumab — also filed as LN-144, Pembrolizumab
- Biological: Pembrolizumab with Optional Crossover Period
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate and Progression Free Survival
measured 5 years total duration
Permalink · IOVA's whole pipeline · Catalyst calendar · Every registered study · What changed